| Schedule of Significant Expense Categories and Consolidated Net Loss Details |
The
following is a summary of the significant expense categories and consolidated net loss details provided to the CODM:
| | |
Three Months Ended
March 31, | |
| | |
2025 | | |
2024 | |
| Segment operating expenses: | |
| | |
| |
| Research and development: | |
| | |
| |
| GEM-AKI, GEM-CKD and GEM-PSI clinical study expenses | |
$ | 470,578 | | |
$ | 333,225 | |
| Other expenses(1) | |
| 23,613 | | |
| 89,015 | |
| Personnel expenses (including stock-based compensation) | |
| 364,639 | | |
| 295,342 | |
| General and administrative | |
| 1,236,157 | | |
| 1,184,556 | |
| Change in fair value of warrant liability | |
| (1,417 | ) | |
| (68,427 | ) |
| Other income (expense), net(2) | |
| (42,485 | ) | |
| 847,722 | |
| Net loss | |
$ | (2,051,085 | ) | |
$ | (2,681,433 | ) |
| (1) | Other research and development expenses primarily consist of facilities charges, third party consultant costs, costs related to other product candidates, and other unallocated costs. | | (2) | Clinical trial related settlement expenses with A-IR Clinical Research Ltd., foreign currency transaction gains and losses and interest income from our cash balances in savings accounts. |
|
The following is a summary of the significant expense categories and consolidated net loss details provided to
the CODM:
| | |
Year Ended
December 31, | |
| | |
2024 | | |
2023 | |
| Segment operating expenses: | |
| | |
| |
| Research and development: | |
| | |
| |
| Product Candidates clinical study expenses | |
$ | 1,681,731 | | |
$ | 209,702 | |
| Manufacturing expenses | |
| 390,022 | | |
| 697,429 | |
| Other program expenses(1) | |
| 77,679 | | |
| 2,190,493 | |
| Other expenses(2) | |
| 172,369 | | |
| 282,948 | |
| Personnel expenses (including stock-based compensation) | |
| 1,227,195 | | |
| 765,330 | |
| General and administrative | |
| 4,426,113 | | |
| 4,510,762 | |
| Change in fair value of warrant liability | |
| (81,441 | ) | |
| (8,328,937 | ) |
| Other (expense) income, net(3) | |
| 7,144,868 | | |
| (207,473 | ) |
| Net loss | |
$ | (15,038,536 | ) | |
$ | (120,254 | ) |
| (1) | Other program expenses include pre-clinical costs and clinical
preparation costs primarily for our Product Candidates. |
| (2) | Other research and development expenses primarily consist
of facilities charges, third party consultant costs, costs related to other product candidates, and other unallocated costs. |
| (3) | LifeSci Capital LLC judgment expense, reimbursement of costs,
clinical trial related settlement expenses with A-IR Clinical Research Ltd., expense in connection with the deferred underwriting commissions,
foreign currency transaction gains and losses and interest income from our cash balances in savings accounts. |
|